Context Therapeutics Q2 net loss widens, cash funds ops into 2027

Context Therapeutics

06/08/2025 22:39

Overview

Context Q2 net loss widens to $8.8 mln from $2.3 mln last year

Outlook

Cash and cash equivalents total $83.5 mln, funding operations into 2027

Result Drivers

R&D EXPENSES - Increase driven by development of CTIM-76, CT-95, and CT-202

CLINICAL PIPELINE - Focus on progressing trials for CTIM-76 and CT-95, with dose escalation data expected in 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$8.80 mln
Q2 Basic EPS
-$0.09


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Context Therapeutics Inc is $5.00, about 86% above its August 5 closing price of $0.70

Press Release: ID:nGNX5zGStQ

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)